Benitec Biopharma Ltd ADR Market Cap ($420.65 Million)
Market Cap & Net Worth: Benitec Biopharma Ltd ADR (BNTC)
Benitec Biopharma Ltd ADR market cap. Benitec Biopharma Ltd ADR (NASDAQ:BNTC) has a market capitalization of $420.65 Million ($420.65 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12796 globally and #3178 in its home market, demonstrating a -6.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Benitec Biopharma Ltd ADR's stock price $12.70 by its total outstanding shares 34254907 (34.25 Million). Also see cash efficiency ratio of Benitec Biopharma Ltd ADR for how efficiently the company converts equity into cash flow.
Benitec Biopharma Ltd ADR Market Cap History (2015–2026)
Benitec Biopharma Ltd ADR market cap history from 2015 to 2026. Data shows change from $34.46 Billion to $299.39 Million (-36.82% CAGR). Check Benitec Biopharma Ltd ADR (BNTC) share price today for real-time trading data and today's change.
Index Memberships
Benitec Biopharma Ltd ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #350 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1272 of 3165 |
Weight: Benitec Biopharma Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Benitec Biopharma Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Benitec Biopharma Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Benitec Biopharma Ltd ADR equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2002.96x
Benitec Biopharma Ltd ADR's market cap is 2002.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $13.11 Billion | $346.51K | -$18.50 Million | 37846.22x | N/A |
| 2017 | $25.37 Billion | $450.31K | -$4.37 Million | 56340.54x | N/A |
| 2018 | $13.10 Billion | $455.45K | -$8.55 Million | 28768.51x | N/A |
| 2019 | $4.45 Billion | $11.32 Million | $2.87 Million | 393.65x | 1553.74x |
| 2020 | $1.75 Billion | $97.00K | -$8.27 Million | 18010.31x | N/A |
| 2021 | $1.53 Billion | $59.00K | -$13.88 Million | 25859.55x | N/A |
| 2022 | $99.00 Million | $73.00K | -$18.21 Million | 1356.12x | N/A |
| 2023 | $110.64 Million | $75.00K | -$19.56 Million | 1475.24x | N/A |
| 2024 | $432.64 Million | $216.00K | -$21.75 Million | 2002.96x | N/A |
Competitor Companies of BNTC by Market Capitalization
Companies near Benitec Biopharma Ltd ADR in the global market cap rankings as of November 1, 2026. Also see Benitec Biopharma Ltd ADR total assets for a full breakdown of the balance sheet.
Key companies related to Benitec Biopharma Ltd ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Benitec Biopharma Ltd ADR (2015–2026)
Market capitalization of Benitec Biopharma Ltd ADR from 2015 to today. Between 2015 and today, Benitec Biopharma Ltd ADR's market cap moved from $34.46 Billion to $ 299.39 Million, with a yearly change of -36.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $299.39 Million | -35.12% |
| 2025 | $461.41 Million | +6.65% |
| 2024 | $432.64 Million | +291.02% |
| 2023 | $110.64 Million | +11.76% |
| 2022 | $99.00 Million | -93.51% |
| 2021 | $1.53 Billion | -12.67% |
| 2020 | $1.75 Billion | -60.78% |
| 2019 | $4.45 Billion | -66.00% |
| 2018 | $13.10 Billion | -48.36% |
| 2017 | $25.37 Billion | +93.46% |
| 2016 | $13.11 Billion | -61.94% |
| 2015 | $34.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Benitec Biopharma Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $420.65 Million USD |
| MoneyControl | $420.65 Million USD |
| MarketWatch | $420.65 Million USD |
| marketcap.company | $420.65 Million USD |
| Reuters | $420.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single a… Read more